Vaccine Efficacy in Malaria Immunization

Malaria immunisation seeks to prevent Plasmodium infection by eliciting immune responses against the parasite before it reaches the symptomatic blood stage. The most advanced candidate, RTS,S/AS01, targets the circumsporozoite protein on sporozoites, achieving modest protective efficacy of 30–50% in young children that wanes over time. Research has broadened to include antigens such as RH5 and PvDBPII, alongside refined adjuvant systems and dosing schedules designed to boost the magnitude and durability of protective antibodies. Cutting-edge techniques—including multiplex immunoassays, systems serology and single-cell transcriptomics—have revealed that both antibody quantity and quality, including fine specificity and Fc-mediated functions, underpin clinical protection. Implementation studies have demonstrated that these vaccines can substantially reduce severe disease and mortality when integrated into national immunisation programmes. Ongoing optimisation of antigen design, adjuvant formulations and booster regimens holds global significance for reducing malaria morbidity and advancing eradication efforts.

Research from Nature Portfolio

Recent studies have dissected the humoral correlates of protection by examining antibody responses to distinct regions of the circumsporozoite protein. A seminal analysis demonstrated that elevated post-vaccination titres directed at the NANP repeat region, combined with high avidity for the C-terminal domain, are significantly associated with reduced clinical malaria risk. These findings have established quantitative and qualitative antibody benchmarks, guiding the development and evaluation of next-generation vaccine candidates.

Vaccine Efficacy in Malaria Immunization publication trend

The graph below shows the total number of articles in vaccine efficacy in malaria immunization across all publications each year (not limited to Nature Index journals).

Technical terms

Circumsporozoite protein (CSP): The major surface antigen of the Plasmodium falciparum sporozoite stage, and target of first-generation vaccines.

Antibody avidity: The overall binding strength of polyclonal antibodies to an antigen, reflecting affinity maturation and functional potency.

Fractional dosing: A strategy in which a reduced antigen or adjuvant dose is administered at extended intervals to enhance immune memory and durability.

FcRn binding: Interaction of IgG with the neonatal Fc receptor, which extends antibody half-life and influences tissue distribution.

Immunogenicity: The ability of a vaccine to provoke specific immune responses, commonly measured by antibody titres and cellular markers.

References

1. Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. The Lancet (2024).
2. Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines. npj Vaccines (2025).
3. Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. JCI Insight (2023).
4. Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens. Frontiers in Immunology (2024).
5. RTS,S/AS01 vaccine (Mosquirix™): an overview. Human Vaccines & Immunotherapeutics (2019).
6. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications (2019).